St John's wort drug interactions: the CYP3A4 inducer problem

St John's wort (Hypericum perforatum) is one of the most rigorously studied herbal antidepressants — multiple meta-analyses support its efficacy for mild to moderate depression at standardized doses. It is also one of the most clinically dangerous botanicals because of a single mechanism: potent induction of the CYP3A4 enzyme system, which metabolizes roughly half of all prescription drugs. Patients picking up an over-the-counter mood supplement from a health food store often have no idea they are starting a drug-clearance accelerator.

The active compound and the mechanism

St John's wort contains hyperforin and hypericin among other bioactive constituents. Hyperforin is the leading interaction-driving compound: it binds to and activates the pregnane X receptor (PXR), a nuclear receptor that transcriptionally upregulates CYP3A4, CYP2C9, CYP2C19, CYP1A2 (less strongly), and P-glycoprotein. The result is accelerated clearance of substrate drugs and reduced plasma levels — sometimes to subtherapeutic [1]. The induction takes 10–14 days to peak and persists for 1–2 weeks after discontinuation.

The transplant rejection case series

The single most dramatic warning came from organ transplant recipients on cyclosporine. Multiple case reports in the late 1990s and early 2000s described acute graft rejection after patients began St John's wort, with plasma cyclosporine dropping by 30–60%. Similar reports followed for tacrolimus and sirolimus. The mechanism is induction of both CYP3A4 (which metabolizes these drugs) and P-glycoprotein (which limits their absorption) [2]. Transplant pharmacy guidelines treat St John's wort as absolutely contraindicated.

Contraceptive failure

Estrogen and progestin in combined oral contraceptives are CYP3A4 substrates. Multiple case series describe breakthrough bleeding and unintended pregnancies in women taking St John's wort with combined hormonal contraception. The European Medicines Agency and the U.S. FDA have both issued warnings. The risk applies to oral pills, patches, and possibly the vaginal ring; injected and intrauterine progestin-only methods are less affected [3].

HIV antiretrovirals and protease inhibitors

St John's wort reduces plasma indinavir AUC by 57% and similarly lowers other protease inhibitors and NNRTIs. The result can be virologic failure and resistance emergence. The FDA issued a Public Health Advisory in 2000 specifically about this interaction. HIV pharmacotherapy guidelines list St John's wort as contraindicated with most antiretroviral regimens [4].

Direct oral anticoagulants and warfarin

Warfarin is metabolized by CYP2C9. St John's wort reduces warfarin AUC and lowers INR, increasing thrombotic risk. The direct oral anticoagulants (apixaban, rivaroxaban, edoxaban) are CYP3A4 and P-glycoprotein substrates and are similarly reduced — case reports describe stroke and venous thromboembolism in patients who began St John's wort while on DOAC therapy [5].

SSRIs and serotonin syndrome

The opposite-direction risk also exists. St John's wort has serotonergic activity in vitro and case reports describe serotonin syndrome when it is combined with SSRIs, SNRIs, MAOIs, tramadol, or triptans. The mechanism is pharmacodynamic rather than pharmacokinetic. Symptoms include agitation, tachycardia, hyperthermia, and clonus. Serotonin syndrome is rare but potentially fatal [6].

Other clinically important interactions

Reduced plasma levels have been documented for: digoxin, statins (particularly atorvastatin and simvastatin), calcium channel blockers, immunosuppressants beyond cyclosporine, methadone, certain anticonvulsants (carbamazepine paradoxically goes up because of complex enzyme effects), and oncology agents including imatinib and irinotecan. Methotrexate clearance is also affected. The list is long enough that the practical rule for clinicians is to treat St John's wort as interacting with most CYP3A4 substrates until proven otherwise.

What patients and clinicians should do

St John's wort can be a reasonable monotherapy choice for adults with mild depression who are taking no other medications and have no significant medical conditions. It should not be used in patients on antiretrovirals, transplant immunosuppressants, DOACs or warfarin, hormonal contraception, or any CYP3A4-metabolized cardiovascular drug. Patients starting prescription medications should disclose St John's wort use to their pharmacist. Patients stopping it before surgery or starting a new drug should allow 14 days for enzyme induction to wash out before assuming normal clearance has returned.

The bottom line

St John's wort is one of the few herbal antidepressants with positive efficacy data. It is also one of the most consequential herb-drug interaction risks in routine practice. Patients on any chronic prescription medication should not take it without checking interactions explicitly. The fact that it is sold over the counter without prescription oversight makes the risk worse, not better, because patients usually do not think of supplements as drugs.